<DOC>
	<DOCNO>NCT00397501</DOCNO>
	<brief_summary>RATIONALE : Osmotic blood-brain barrier disruption use certain drug , mannitol , open blood vessel around brain allow tumor-killing substance carry directly brain . Drugs use chemotherapy , methotrexate carboplatin , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , trastuzumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Trastuzumab may also help methotrexate carboplatin work well make tumor cell sensitive drug . Giving osmotic blood-brain barrier disruption together methotrexate , carboplatin , trastuzumab may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose carboplatin give together methotrexate trastuzumab mannitol treat woman breast cancer spread brain .</brief_summary>
	<brief_title>BBBD Followed By Methotrexate Carboplatin With Without Trastuzumab Treating Women With Breast Cancer That Has Spread Brain</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety toxicity associate blood-brain barrier disruption comprise transfemoral mannitol follow methotrexate carboplatin without trastuzumab ( Herceptin® ) woman brain metastasis secondary breast cancer . ( Phase I ) - Determine overall survival exceed 5 month patient Human Epidermal growth factor Receptor 2 ( HER2 ) -positive HER2-negative disease treat regimen . ( Phase II ) Secondary - Determine overall survival patient . - Compare event-free overall survival , steroid use , response rate , time best response patient HER2-positive vs HER2-negative disease . - Assess quality life patient treat regimen . - Assess neuropsychological effect treatment regimen patient . - Determine cerebrospinal fluid level trastuzumab blood-brain barrier disruption . OUTLINE : This multicenter , phase I , pilot , dose-finding study carboplatin follow phase II , open-label study . - Phase I : Patients undergo osmotic blood-brain barrier disruption ( BBBD ) comprise mannitol transfemoral catheterization follow methotrexate intra-arterially ( IA ) 10 minute carboplatin IA 10 minute day 1 2 . Patients also receive sodium thiosulfate IV 15 minute 4 8 hour dose carboplatin ; leucovorin calcium IV orally every 6 hour day 3-9 ; pegfilgrastim subcutaneously ( SC ) day 4 filgrastim ( G-CSF ) SC begin day 4 continue blood count recover ( 7-10 day ) . Patients HER-2 positive disease receive trastuzumab ( Herceptin® ) IV 90 minute within 48 hour prior BBBD weekly 3 week ( BBBD therapy session ) . Treatment repeat every 4 week 12 month absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive decrease dos carboplatin and/or methotrexate propose dose well tolerate . Dose-limiting toxicity define grade IV hematologic toxicity delay subsequent treatment course 4 week OR grade III/IV nonhematologic toxicity without recovery 14 day course treatment . - Phase II : Patients undergo BBBD phase I receive carboplatin methotrexate dos determine phase I . Patients also receive sodium thiosulfate , leucovorin calcium , pegfilgrastim G-CSF phase I . Patients HER2-positive disease also receive trastuzumab phase I. Neuropsychological assessment perform baseline , every 6 month treatment , every 6 month 1 year , annually thereafter . Quality life assess baseline , every 3 month treatment , completion study treatment , every 6 month 1 year , annually thereafter . After completion study therapy , patient follow periodically . PROJECTED ACCRUAL : A total 78 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Sodium thiosulfate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm breast cancer metastatic central nervous system ( document brain biopsy , cytology [ analysis cerebrospinal fluid ] ) OR radiographic evidence brain metastasis diagnosis systemic breast cancer Patients must stable systemic disease determine CT scan chest , abdomen , pelvis HER2positive negative disease fluorescent situ hybridization ( FISH ) immunohistochemistry Patients HER2positive disease sign intracranial herniation and/or spinal block may first undergo intraarterial chemotherapy study ( carboplatin , methotrexate , trastuzumab [ Herceptin® ] route use study ) radiographically show safe undergo blood brain barrier disruption , point may enrol study Hormone receptor status specify PATIENT CHARACTERISTICS : Female Menopausal status specify ECOG performance status ( PS ) 02 OR Karnofsky PS 60100 % Life expectancy &gt; 6 week Hematocrit ≥ 25 % WBC ≥ 2,500/mm³ Absolute neutrophil count ≥ 1,200/mm³ Platelet count ≥100,000/mm³ Creatinine clearance ≥ 50 mL/min ( eligible fulldose methotrexate ) ( 3049 mL/min allow patient receive reduceddose methotrexate ) Bilirubin ≤ 2.0 time upper limit normal LVEF normal echocardiogram MUGA Adequate pulmonary cardiac function tolerate general anesthesia determine physical examination history No New York Heart Association class IIIIV heart disease Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known allergy trastuzumab ( HER2positive patient ) , carboplatin , methotrexate , sodium thiosulfate No hepatitis B C positivity No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection ( e.g. , HIV ) Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would limit compliance study requirement PRIOR CONCURRENT THERAPY : Prior surgery biopsy allow Prior chemotherapy radiation therapy metastatic breast cancer allow No radiation cytotoxic chemotherapy within past 4 week ( except trastuzumab hormone therapy part patient 's ongoing treatment [ e.g. , aromatase inhibitor estrogen receptor positive patient ] ) No noncytotoxic regimen ( e.g. , targeted oral agent ) within past 2 week No investigational agent within past 4 week No concurrent anticancer agent therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>cognitive/functional effect</keyword>
	<keyword>psychosocial effect cancer treatment</keyword>
	<keyword>drug/agent toxicity tissue/organ</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>adult tumor metastatic brain</keyword>
</DOC>